<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495908</url>
  </required_header>
  <id_info>
    <org_study_id>VGo Switch</org_study_id>
    <nct_id>NCT03495908</nct_id>
  </id_info>
  <brief_title>Regular Insulin vs Rapid Insulin Delivered by V-Go</brief_title>
  <official_title>Efficacy and Safety Comparison Between U-100 Regular Human Insulin and Rapid Acting Insulin When Delivered by VGo Wearable Insulin Delivery in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Coast Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeritas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dallas Diabetes Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East Coast Institute for Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect data about how well U-100 Regular Human Insulin can be&#xD;
      used in the V-Go Insulin Delivery Device compared to U-100 Rapid Acting Insulin in the V-Go&#xD;
      Insulin Delivery Device. The data collected will be used to see how much subjects' blood&#xD;
      sugar levels change over time after they switch from using U-100 Rapid Acting Insulin to&#xD;
      U-100 Regular Human Insulin within their V-Go Insulin Delivery Device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">August 12, 2019</completion_date>
  <primary_completion_date type="Actual">August 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Per protocol population for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Prevalence of Hypoglycemic Events Between Groups Based on 7- Point Glucose Profiles.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Number of participants reporting 7-Point Hypoglycemia based on 7-point glucose profiles. Intent-to-treat (ITT) Population N=136</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Incidence of Hypoglycemic Events Between Groups Based on 7- Point Glucose Profiles.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Level 1 (≤70 mg/dL or (&lt;3.9 mmol/L)) and level 2 hypoglycemia (&lt;54 mg/dL (&lt;3.0 mmol/L)) events are analyzed. No level 3 events were reported for either group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Change in Total Daily Doses (Units/kg) of Insulin Between Groups After 12 Weeks of Treatment.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Between group differences in Insulin TDD U/day. Intent-to-treat Population, n=136</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Change in Total Daily Doses (TDD), Units/Day of Insulin Between Groups After 12 Weeks of Treatment.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>RHI versus RAI, comparing the change in total daily dose (TDD), units/day of insulin between groups. Intent-to-treat Population N=136</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Difference in Direct Pharmacy Insulin Costs to Insurance Payor Using Wholesale Acquisition Costs Between Groups.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Cost Analysis for direct diabetes-related pharmacy insulin costs. All insulin costs are normalized to 30-days and based on the prescribed TDD at V2 (Baseline) and at study end (EOS) and multiplying the insulin dose in units by the average unit cost of the prescribed insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Intent-to-treat Population Secondary Outcome, Non-inferiority Hypothesis.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Intent-to-treat population secondary outcome for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate the Change in Glucose Patterns Between Groups Based on 7-point Glucose Profiles.</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Evaluate the change between baseline and week 12 in glucose patterns between groups based on 7-point glucose profiles.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>VGo with Regular Human Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VGo with Rapid Acting Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VGo</intervention_name>
    <description>Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
    <arm_group_label>VGo with Rapid Acting Insulin</arm_group_label>
    <arm_group_label>VGo with Regular Human Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 21 years at time of study enrollment&#xD;
&#xD;
          2. Diagnosed with T2D for at least 6 months prior to screening&#xD;
&#xD;
          3. Screening visit A1C ≥ 7.0% and ≤ 12.5%&#xD;
&#xD;
          4. Prescribed a stable (less than 20% change in the past 30 days) of rapid acting U-100&#xD;
             insulin delivered via V-Go insulin delivery device&#xD;
&#xD;
          5. Ability to read and understand English&#xD;
&#xD;
          6. Willing to complete all study related activities&#xD;
&#xD;
          7. Willing and able to understand and sign a written ICF indicating that they agree to&#xD;
             participate and have been informed of all pertinent aspects of the study&#xD;
&#xD;
          8. Must be willing to take and record 7 glucose measurements per time period (pre-morning&#xD;
             meal (fasting), pre-midday meal, pre-evening meal, and 2-hours after the start of the&#xD;
             morning, midday, and evening meals, and at bedtime) three times throughout the study&#xD;
             (prior to Visit 2, 3, and 4).&#xD;
&#xD;
          9. Completed a 7-point glucose profile prior to Visit 2&#xD;
&#xD;
         10. Able (by insurance or financial means) to cover the initial investment and ongoing&#xD;
             cost of the V-Go insulin delivery device, insulin (current rapid acting insulin or&#xD;
             potential new regular human insulin), personal glucometer and supplies for the length&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with confirmed Type 1 diabetes&#xD;
&#xD;
          2. More than 1 episode of severe hypoglycemia (defined as requiring third party&#xD;
             assistance) within 3 months of study entry&#xD;
&#xD;
          3. History of hypoglycemia unawareness&#xD;
&#xD;
          4. Require supplemental insulin in addition to V-Go therapy&#xD;
&#xD;
          5. Woman of child-bearing potential who has a positive pregnancy test at screening or&#xD;
             plans to become pregnant during the course of the study. Women of childbearing&#xD;
             potential are defined as any female who has experienced menarche and who it NOT&#xD;
             permanently sterile of postmenopausal. Postmenopausal is defined as 12 consecutive&#xD;
             months with no menses without and alternative medical cause.&#xD;
&#xD;
          6. Woman who are lactating.&#xD;
&#xD;
          7. Use of any oral, injectable, or IV steroids within 8 weeks from time of screening&#xD;
             visit, or plans to take any oral, injectable, or IV steroids during the course of the&#xD;
             study&#xD;
&#xD;
          8. A recipient of a solid organ transplant&#xD;
&#xD;
          9. Current use of U-100 RHI in V-Go within 90 days of screening&#xD;
&#xD;
         10. Current use of U-500 RHI in V-Go within 90 days of screening&#xD;
&#xD;
         11. Currently on dialysis&#xD;
&#xD;
         12. Medical or other problems which in the opinion of the investigator will render study&#xD;
             participation unsafe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <results_first_submitted>December 23, 2020</results_first_submitted>
  <results_first_submitted_qc>December 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VGo</keyword>
  <keyword>Insulin</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03495908/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VGo With Regular Human Insulin</title>
          <description>Switch to U-100 Regular Human Insulin (RHI) delivered by the V-Go insulin delivery device.</description>
        </group>
        <group group_id="P2">
          <title>VGo With Rapid Acting Insulin</title>
          <description>Continue on U-100 Rapid Acting Insulin (RAI) delivered by the V-Go insulin delivery device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No documented reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VGo With Regular Human Insulin</title>
          <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
        </group>
        <group group_id="B2">
          <title>VGo With Rapid Acting Insulin</title>
          <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="10.9"/>
                    <measurement group_id="B2" value="60.2" spread="11.6"/>
                    <measurement group_id="B3" value="61.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percentage of Hemoglobin A1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="1.4"/>
                    <measurement group_id="B2" value="8.5" spread="1.5"/>
                    <measurement group_id="B3" value="8.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis.</title>
        <description>Per protocol population for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis.</title>
          <description>Per protocol population for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.</description>
          <population>Per protocol</population>
          <units>percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5966" lower_limit="-0.9041" upper_limit="-0.2892"/>
                    <measurement group_id="O2" value="-0.3759" lower_limit="-0.6973" upper_limit="-0.05455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RHI - RAI estimated treatment difference (ETD) in HbA1c. Per-protocol analysis is the pre-specified primary outcome.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.4% HbA1c</non_inferiority_desc>
            <p_value>0.007</p_value>
            <p_value_desc>Non-inferiority p-value based on the 0.4% non-inferiority margin</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2207</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6654</ci_lower_limit>
            <ci_upper_limit>0.2241</ci_upper_limit>
            <estimate_desc>RHI - RAI estimated treatment difference. Upper confidence interval 0.22 is less than the 0.4% non-inferiority margin.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Prevalence of Hypoglycemic Events Between Groups Based on 7- Point Glucose Profiles.</title>
        <description>Number of participants reporting 7-Point Hypoglycemia based on 7-point glucose profiles. Intent-to-treat (ITT) Population N=136</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Prevalence of Hypoglycemic Events Between Groups Based on 7- Point Glucose Profiles.</title>
          <description>Number of participants reporting 7-Point Hypoglycemia based on 7-point glucose profiles. Intent-to-treat (ITT) Population N=136</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-randomization prevalence of hypoglycemia based on 7-point glucose profiles.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Comparison of Post-randomization prevalence of hypoglycemia based on 7-point glucose profiles.</non_inferiority_desc>
            <p_value>.82</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Incidence of Hypoglycemic Events Between Groups Based on 7- Point Glucose Profiles.</title>
        <description>Level 1 (≤70 mg/dL or (&lt;3.9 mmol/L)) and level 2 hypoglycemia (&lt;54 mg/dL (&lt;3.0 mmol/L)) events are analyzed. No level 3 events were reported for either group.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-treat safety population, n=136</population>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Incidence of Hypoglycemic Events Between Groups Based on 7- Point Glucose Profiles.</title>
          <description>Level 1 (≤70 mg/dL or (&lt;3.9 mmol/L)) and level 2 hypoglycemia (&lt;54 mg/dL (&lt;3.0 mmol/L)) events are analyzed. No level 3 events were reported for either group.</description>
          <population>Intent-to-treat safety population, n=136</population>
          <units>Events per person weeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069"/>
                    <measurement group_id="O2" value="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016"/>
                    <measurement group_id="O2" value="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Level 1 (≤70 mg/dL or (&lt;3.9 mmol/L)) and level 2 hypoglycemia (&lt;54 mg/dL (&lt;3.0 mmol/L)) events are analyzed. No level 3 events were reported for either group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysis of the 7-point profiles within the ITT population (n=136)</non_inferiority_desc>
            <p_value>0.861</p_value>
            <p_value_desc>Results are from a Poisson regression model with repeated measures; generalized estimating equations (GEE) approach.</p_value_desc>
            <method>Regression, Poisson</method>
            <method_desc>Poisson regression model with repeated measures; generalized estimating equations (GEE) approach</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.925</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.386</ci_lower_limit>
            <ci_upper_limit>2.217</ci_upper_limit>
            <estimate_desc>The incidence rate ratio quantitates the risk of hypoglycemia in the RHI group (RR numerator) compared with the RAI group (RR numerator). Results from Poisson regression model with repeated measures; generalized estimating equations (GEE) approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Change in Total Daily Doses (Units/kg) of Insulin Between Groups After 12 Weeks of Treatment.</title>
        <description>Between group differences in Insulin TDD U/day. Intent-to-treat Population, n=136</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Change in Total Daily Doses (Units/kg) of Insulin Between Groups After 12 Weeks of Treatment.</title>
          <description>Between group differences in Insulin TDD U/day. Intent-to-treat Population, n=136</description>
          <units>units/kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline TDD U/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.61" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.61" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of study TDD U/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.62" upper_limit="0.70"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.61" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>RHI versus RAI for Insulin Intent-to-treat Population N=136 Mixed Model Estimates for Insulin TDD U/kg I</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.415</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.01073</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03674</ci_lower_limit>
            <ci_upper_limit>0.01528</ci_upper_limit>
            <estimate_desc>Between Group Comparison (RHI-RAI) Estimated Treatment Difference (ETD) mixed effects model analysis</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Change in Total Daily Doses (TDD), Units/Day of Insulin Between Groups After 12 Weeks of Treatment.</title>
        <description>RHI versus RAI, comparing the change in total daily dose (TDD), units/day of insulin between groups. Intent-to-treat Population N=136</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-treat Population N=136</population>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Change in Total Daily Doses (TDD), Units/Day of Insulin Between Groups After 12 Weeks of Treatment.</title>
          <description>RHI versus RAI, comparing the change in total daily dose (TDD), units/day of insulin between groups. Intent-to-treat Population N=136</description>
          <population>Intent-to-treat Population N=136</population>
          <units>units/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Insulin TDD, U/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.13" lower_limit="57.66" upper_limit="64.60"/>
                    <measurement group_id="O2" value="60.90" lower_limit="57.37" upper_limit="64.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study Insulin TDD, U/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.90" lower_limit="58.38" upper_limit="65.41"/>
                    <measurement group_id="O2" value="62.74" lower_limit="59.15" upper_limit="66.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.320</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0776</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2139</ci_lower_limit>
            <ci_upper_limit>1.0587</ci_upper_limit>
            <estimate_desc>Between Group Comparison (RHI-RAI) Estimated Treatment Difference (ETD) mixed effects model analysis</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Difference in Direct Pharmacy Insulin Costs to Insurance Payor Using Wholesale Acquisition Costs Between Groups.</title>
        <description>Cost Analysis for direct diabetes-related pharmacy insulin costs. All insulin costs are normalized to 30-days and based on the prescribed TDD at V2 (Baseline) and at study end (EOS) and multiplying the insulin dose in units by the average unit cost of the prescribed insulin</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Per-protocol population, n=113</population>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Difference in Direct Pharmacy Insulin Costs to Insurance Payor Using Wholesale Acquisition Costs Between Groups.</title>
          <description>Cost Analysis for direct diabetes-related pharmacy insulin costs. All insulin costs are normalized to 30-days and based on the prescribed TDD at V2 (Baseline) and at study end (EOS) and multiplying the insulin dose in units by the average unit cost of the prescribed insulin</description>
          <population>Per-protocol population, n=113</population>
          <units>US dollar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Insulin Cost, $</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="515.68" spread="123.01"/>
                    <measurement group_id="O2" value="518.31" spread="124.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study Insulin Cost, $</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.19" spread="61.39"/>
                    <measurement group_id="O2" value="533.66" spread="118.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-265.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-288.60</ci_lower_limit>
            <ci_upper_limit>-243.11</ci_upper_limit>
            <estimate_desc>Estimated Treatment Difference (RHI-RAI) from repeated measures mixed model least squares estimates</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Intent-to-treat Population Secondary Outcome, Non-inferiority Hypothesis.</title>
        <description>Intent-to-treat population secondary outcome for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-treat secondary outcome of HbA1c response for assessment of non-inferiority of RHI compared to RAI</population>
        <group_list>
          <group group_id="O1">
            <title>VGo With Regular Human Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
          <group group_id="O2">
            <title>VGo With Rapid Acting Insulin</title>
            <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Intent-to-treat Population Secondary Outcome, Non-inferiority Hypothesis.</title>
          <description>Intent-to-treat population secondary outcome for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.</description>
          <population>Intent-to-treat secondary outcome of HbA1c response for assessment of non-inferiority of RHI compared to RAI</population>
          <units>percentage of Hemoglobin A1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5484" lower_limit="-0.8618" upper_limit="-0.2349"/>
                    <measurement group_id="O2" value="-0.4167" lower_limit="-0.7425" upper_limit="-0.09088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intent-to-treat secondary outcome of HbA1c response for assessment of non-inferiority of RHI compared to RAI</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Change in A1C Non-inferiority Margin is 0.4%</non_inferiority_desc>
            <p_value>0.02</p_value>
            <p_value_desc>p-value for non-inferiority</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1317</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5838</ci_lower_limit>
            <ci_upper_limit>0.3205</ci_upper_limit>
            <estimate_desc>Between Group Difference (RHI-RAI) mixed effects repeated measures model analysis.Upper confidence interval 0.32 is less than the 0.4% non-inferiority margin.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluate the Change in Glucose Patterns Between Groups Based on 7-point Glucose Profiles.</title>
        <description>Evaluate the change between baseline and week 12 in glucose patterns between groups based on 7-point glucose profiles.</description>
        <time_frame>Baseline and Week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks. From randomization to end of study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VGo With Regular Human Insulin</title>
          <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
        </group>
        <group group_id="E2">
          <title>VGo With Rapid Acting Insulin</title>
          <description>VGo: Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Worsening of A-fib</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Worsening of CHF</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral Papillary Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upset stomach</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Skin irritation, welt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pablo F Mora</name_or_title>
      <organization>The University of Texas Southwestern Medical Center</organization>
      <phone>469-585-0000</phone>
      <email>pf_mora@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

